Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an announcement.
CSPC Pharmaceutical Group Limited has received approval from the U.S. FDA to conduct clinical trials for its new siRNA drug, SYH2070 Injection, in the United States. This drug, designed for liver-targeted delivery, shows promise in treating hypertriglyceridemia or mixed hyperlipidemia by effectively reducing ANGPTL3 levels. Preclinical studies indicate that SYH2070 offers superior pharmacological activity and a long-lasting therapeutic effect, positioning it as a potential leader in its category with significant clinical development value.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is known for its research and development efforts, particularly in the area of small interfering RNA (siRNA) drugs.
Average Trading Volume: 171,262,612
Technical Sentiment Signal: Buy
Current Market Cap: HK$111.6B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.